Ahmed M Musa

Summary

Affiliation: University of Khartoum
Country: Sudan

Publications

  1. pmc Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
    Raymond Omollo
    Drugs for Neglected Diseases initiative DNDi Africa, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
    Trials 12:166. 2011
  2. pmc Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study
    Ahmed M Musa
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    PLoS Negl Trop Dis 4:e855. 2010
  3. ncbi request reprint Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)
    A M Musa
    Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
    Ann Trop Med Parasitol 99:563-9. 2005
  4. ncbi request reprint Antimony-induced cerebellar ataxia
    Eltahir Awad G Khalil
    Department of Clinical Pathology and Immunology Institute of Endemic Diseases, University of Khartoum, PO Box 45235, Khartoum, Sudan
    Saudi Med J 27:90-2. 2006
  5. ncbi request reprint Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers
    A A Kamil
    Leishmaniasis Research Group, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Trans R Soc Trop Med Hyg 97:365-8. 2003
  6. doi request reprint Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
    Eltahir A G Khalil
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    PLoS Negl Trop Dis 8:e2613. 2014
  7. doi request reprint Revival of a focus of visceral leishmaniasis in central Sudan
    E A G Khalil
    The Leishmaniasis Research Group, Institute of Endemic Diseases, University of Khartoum, P O Box 45235, Khartoum, Sudan
    Ann Trop Med Parasitol 102:79-80. 2008
  8. pmc Dichotomy of protective cellular immune responses to human visceral leishmaniasis
    E A G Khalil
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Clin Exp Immunol 140:349-53. 2005
  9. pmc Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines
    Mona E E Elfaki
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Hum Vaccin Immunother 8:1769-74. 2012
  10. pmc The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs
    Filip Meheus
    Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    Am J Trop Med Hyg 89:1146-53. 2013

Collaborators

  • M M Mukhtar
  • E E Zijlstra
  • Asrat Hailu
  • Tansy Edwards
  • Manica Balasegaram
  • Peter G Smith
  • Thomas P C Dorlo
  • Marleen Boelaert
  • Filip Meheus
  • Jenefer M Blackwell
  • Feleke Moges
  • Muntaser E Ibrahim
  • Anne S De Groot
  • A Ismail
  • D L Sacks
  • E A G Khalil
  • Eltahir A G Khalil
  • Ahmed M El-Hassan
  • A M El-Hassan
  • Brima M Younis
  • Raymond Omollo
  • B M Younis
  • M E E Elfaki
  • M A Salih
  • A M Elhassan
  • H S Mohamed
  • Sally Ellis
  • Abuzaid A Abuzaid
  • Monique Wasunna
  • Mona E E Elfaki
  • N A A Elnojomi
  • S Farouk
  • S H Hamad
  • Ahmed A Nimir
  • E N Miller
  • Abdelgadir H Elagib
  • Ammar E Ahmed
  • Eltahir Awad G Khalil
  • Muzamil Mahdi
  • E M Elamin
  • F Modabber
  • F Zicker
  • A A Kamil
  • Teklu Weldegebreal
  • Gerard J Schoone
  • Robert Kimutai
  • Workagegnehu Hailu
  • Sisay Yifru
  • William Haleke
  • Zewdu Hurissa
  • Andres Gutierrez
  • Kawthar A M Salih
  • Dedan Kinoti
  • George Kirigi
  • Neal Alexander
  • Njenga Njoroge
  • E A Khalil
  • Habab M Yassin
  • A Meshasha
  • Abbashar Hussein
  • S H H Elgawi
  • Eltahir A Khalil
  • M O Elhassan
  • I Gamar Eldawla
  • K A Eljaleel
  • Muna H Hussein
  • M El Azhari
  • M M Abdel Hamid
  • I Guizani
  • A M El Hassan
  • P M Kieny
  • N B Ayed
  • A M Y Elkadaro
  • S Guerbouj
  • Elwaleed M Elamin
  • I M Elhassan
  • H W Ghalib
  • Sara E Melville
  • Ahmed M Elhassan

Detail Information

Publications21

  1. pmc Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
    Raymond Omollo
    Drugs for Neglected Diseases initiative DNDi Africa, Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
    Trials 12:166. 2011
    ..The aim of this trial is to identify regimen(s) which are sufficiently promising for future trials in East Africa...
  2. pmc Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study
    Ahmed M Musa
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    PLoS Negl Trop Dis 4:e855. 2010
    ..We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days...
  3. ncbi request reprint Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)
    A M Musa
    Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, University of Khartoum, Sudan
    Ann Trop Med Parasitol 99:563-9. 2005
    ..Once certain favourable clinical signs (the regression and/or darkening of the PKDL lesions) have been noted, the lesions will probably continue to clear without the need for more injections...
  4. ncbi request reprint Antimony-induced cerebellar ataxia
    Eltahir Awad G Khalil
    Department of Clinical Pathology and Immunology Institute of Endemic Diseases, University of Khartoum, PO Box 45235, Khartoum, Sudan
    Saudi Med J 27:90-2. 2006
    ..Like other infectious diseases, neurological manifestations of VL and sodium stibogluconate have been documented. In this report, we present 2 cases of cerebellar ataxia most likely induced by Pentostam, and explain the probable cause...
  5. ncbi request reprint Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers
    A A Kamil
    Leishmaniasis Research Group, Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Trans R Soc Trop Med Hyg 97:365-8. 2003
    ..On the basis of this study we suggest that 100 1 microg of leishmanial protein in the vaccine mixture is a suitable dose for future efficacy studies, as it induced the strongest DTH reaction following vaccination...
  6. doi request reprint Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial
    Eltahir A G Khalil
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    PLoS Negl Trop Dis 8:e2613. 2014
    ..Anti-leishmanial drug regimens that include a single dose AmBisome® could be suitable for eastern African patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown...
  7. doi request reprint Revival of a focus of visceral leishmaniasis in central Sudan
    E A G Khalil
    The Leishmaniasis Research Group, Institute of Endemic Diseases, University of Khartoum, P O Box 45235, Khartoum, Sudan
    Ann Trop Med Parasitol 102:79-80. 2008
  8. pmc Dichotomy of protective cellular immune responses to human visceral leishmaniasis
    E A G Khalil
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Clin Exp Immunol 140:349-53. 2005
    ..Following vaccination and probably cure of VL infection, the IFN-gamma response declines with time while the LST response persists. LST is a simple test that can be used to assess candidate vaccine efficacy...
  9. pmc Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines
    Mona E E Elfaki
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Hum Vaccin Immunother 8:1769-74. 2012
    ..The immunogenicity of these epitopes may be harnessed most effectively in a vaccine delivered in combination with immune-modulating adjuvants. ..
  10. pmc The economic burden of visceral leishmaniasis in Sudan: an assessment of provider and household costs
    Filip Meheus
    Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium Health Economics Unit, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands Drugs for Neglected Diseases Initiative, Geneva, Switzerland
    Am J Trop Med Hyg 89:1146-53. 2013
    ..The length of treatment of 30 days led to important costs for both health providers and households. Alternative treatment regimens that reduce the duration of treatment are urgently needed...
  11. pmc IFNG and IFNGR1 gene polymorphisms and susceptibility to post-kala-azar dermal leishmaniasis in Sudan
    M A Salih
    Institute of Endemic Disease, University of Khartoum, Khartoum, Sudan
    Genes Immun 8:75-8. 2007
    ....
  12. ncbi request reprint The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features
    A M Musa
    Institute of Endemic Diseases, University of Khartoum, P O Box 3516, Khartoum, Sudan
    Ann Trop Med Parasitol 96:765-72. 2002
    ..05). In conclusion, spontaneous healing is commonly seen in Sudanese patients with PKDL. Persistence of the lesions is frequently associated with non-reactivity in the LST and high levels of anti-leishmanial antibodies...
  13. doi request reprint Evaluation of the particle gel diffusion technique for the detection of haemoglobin S in Sudanese patients
    Ahmed A Nimir
    Faculty of Laboratory Medicine, University of Khartoum, Khartoum, Sudan
    Ann Clin Biochem 46:114-6. 2009
    ....
  14. ncbi request reprint Possible predisposing factors for thrombotic cerebrovascular accidents in Sudanese patients
    Abdelgadir H Elagib
    Department of Clinical Pathology and Immunology, Institute of Endemic Diseases, Faculty of Medicine, University of Khartoum, Khartoum, Sudan
    Saudi Med J 29:304-6. 2008
  15. ncbi request reprint Sudanese mucosal leishmaniasis: isolation of a parasite within the Leishmania donovani complex that differs genotypically from L. donovani causing classical visceral leishmaniasis
    Muzamil Mahdi
    Institute of Endemic Diseases, University of Khartoum, P O Box 102, Khartoum, Sudan
    Infect Genet Evol 5:29-33. 2005
    ..donovani and a different geographical distribution, albeit often overlapping with that of L. donovani...
  16. ncbi request reprint The pathogenesis of post kala-azar dermal leishmaniasis from the field to the molecule: does ultraviolet light (UVB) radiation play a role?
    A Ismail
    Department of Clinical Pathology and Immunology, Faculty of Medicine, Institute of Endemic Diseases, University of Khartoum, Medical Sciences Campus, Sudan
    Med Hypotheses 66:993-9. 2006
    ..The Th-1 cytokine IFN-gamma was constantly present. The tissue origin of the Th-1 cells in PKDL is unknown. We believe that the antagonistic action of the different cytokines is the cause of the inflammation and chronicity of PKDL...
  17. doi request reprint Leishmania donovani: genetic diversity of isolates from Sudan characterized by PCR-based RAPD
    S H Hamad
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Exp Parasitol 125:389-93. 2010
    ..In this communication the possible role of isolates diversity in antimonial unresponsiveness and the in vitro changing PCR-RAPD band pattern in SSG-unresponsive strains were discussed...
  18. pmc Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected sudanese population
    S Farouk
    Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Public Health Genomics 13:362-7. 2010
    ..The study aimed to investigate the possible role of interleukin 10 (IL-10) and development of PKDL...
  19. ncbi request reprint Uncommon clinical presentations of cutaneous leishmaniasis in Sudan
    E M Elamin
    Institute of Endemic Diseases, University of Khartoum, P O Box 11463, Khartoum, Sudan
    Trans R Soc Trop Med Hyg 99:803-8. 2005
    ..Leishmania major was found by kDNA PCR in all patients, except one, who had a leishmanioma due to L. donovani. In three patients, including one with a L. tropica like-lesion, the parasites were confirmed as L. major by gp63 PCR-RFLP...
  20. ncbi request reprint Surrogate markers of subtle renal injury in patients with visceral leishmaniasis
    N A A Elnojomi
    The Leishmaniasis Research Group Sudan, The Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan
    Saudi J Kidney Dis Transpl 21:872-5. 2010
    ..In conclusion; subtle renal injury in VL is mainly glomerular. Turbidometry for MA measurement is a simple, inexpensive, sensitive, and specific technique with high predictive values...
  21. ncbi request reprint Post-kala-azar dermal leishmaniasis
    E E Zijlstra
    EEZ is at the Department of Medicine, College of Medicine, Malawi
    Lancet Infect Dis 3:87-98. 2003
    ..Although research has brought many new insights in pathogenesis and management of PKDL, several issues in particular in relation to control remain unsolved and deserve urgent attention...